FDA Approves Hemophilia B Gene Therapy, but Its Cost May Pose Access Problems for Payers
-
Feb 09, 2023
The FDA recently approved the fifth and sixth gene therapies, with four of those decisions coming in the second half of 2022. While payer respondents to a Zitter Insights survey have expressed interest in hemophilia B treatment Hemgenix (etranacogene dezaparvovec-drlb), its price may prove to be an obstacle to coverage.
On Nov. 22, the FDA approved uniQure N.V.’s Hemgenix for the treatment of people at least 18 years old with hemophilia B who currently use factor IX prophylaxis therapy or have current or historical life-threatening hemorrhage or have repeated serious spontaneous bleeding episodes. CSL Behring LLC, a CSL business, will market the gene therapy. The agency gave the first-in-class adeno-associated virus A5-based gene therapy — which previously was known as EtranaDez — priority review and orphan and breakthrough therapy designations.
Read more
© 2024 MMIT
Related Posts
-
![]()
Dec 08
Study Shows Only About One-Third of People With NSCLC Are Benefiting From Appropriate Care
Read more -
![]()
Nov 10
Payers Say They Are Seeing Cost Savings From Shifting to Biosimilars
Read more -
![]()
Nov 10
Oncologists May Prescribe New Neutropenia Agent Over Others in Class, but Therapy Faces Another Challenge
Read more
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.